胰高血糖素样肽受体激动剂对脑卒中影响研究进展

Research progress on the effects of glucagon-like peptide-1 receptor agonists in stroke

脑卒中是一种常见的急性脑血管病,其发病率、死亡率高,目前仍需有效的预防及治疗方法。胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RA)是一种新型降糖药,GLP-1RA在作用于胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体发挥降糖、减重作用的同时还可通过抑制炎症、氧化应激、细胞凋亡和改善血脑屏障通透性等病理生理途径减小脑卒中的梗死面积、促进神经恢复。本文总结了GLP-1在脑卒中发生过程中的变化情况,初步探讨GLP-1RA通过哪些病理机制影响脑卒中的发生发展,同时将GLP-1RA对于脑卒中治疗效果进行了简要综述。

Stroke is a prevalent acute cerebrovascular disease associated with significant morbidity and mortality,which highly demand effective prevention and treatment strategies.Glucagon-like peptide-1 receptor agonists(GLP-1RA)is a novel type of antidiabetic drug that exerts hypoglycemic and weight loss effects on GLP-1 receptors.Additionally,GLP-1RA possess the potential to reduce infarction size and promote nerve recovery by inhibiting inflammation,oxidative stress,apoptosis,and improving blood-brain barrier permeability and other pathologies.This paper provides a comprehensive summary of the role of GLP-1 in stroke occurrence while also explores the underlying mechanisms by which GLP-1RA influences stroke pathogenesis.Furthermore,it briefly reviews the therapeutic efficacy of GLP-RA in managing stroke.